عـرض براءة الإختـراع

Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors

• رقــم البراءة

  US 12,187,726 B1

• المجـال العلمى

  Default Scientific Field - Default Scientific Field

• سنة الإصدار

  2025

• مكتـب التسجيـل

  Default Office - Default Office

• أسماء المخترعين

  Tratrat; Christophe (Al-Ahsa, SA), Haroun; Michelyne (Al-Ahsa, SA)

• نبذة عن البـراءة

  Novel imidazo[1,5-a]pyrido[4,3-e]pyrazine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The imidazo[1,5-a]pyrido[4,3-e]pyrazine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.